Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the … Read full Trend Edge analysis →
| Current Price | $2.10 |
|---|---|
| Market Cap | $1.49B |
| Float | 41.2M |
| Shares Outstanding | 43.8M |
| P/E (Forward) | 40.65 |
| P/E (TTM) | 35.39 |
| Price/Sales (TTM) | 4.35 |
| vs. Analyst Target | +1519.0% to analyst PT |
| Profit Margin | 12.75% |
| Operating Margin (TTM) | 22.70% |
| Revenue (TTM) | $333M |
| Earnings Growth (YoY) | -13.00% |
| Dividend Rate | None |
| Analyst Target Price | $34.00 (2 analysts) |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2017 | $201M | $21.6M | $125M | $46.2M |
| 2018 | $214M | $23.8M | $130M | $39.8M |
| 2019 | $201M | $24.4M | $118M | $43.5M |
| 2020 | $254M | $46.2M | $156M | $75.5M |
| 2021 | $318M | $71.4M | $201M | $108M |
| 2022 | $333M | $42.5M | $188M | $72.0M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Mar 2022 | $111M | $28.8M |
| Jun 2022 | $67.8M | -$7.3M |
| Sep 2022 | $65.7M | $5.7M |
| Dec 2022 | $56.9M | -$29.8M |
| Insider Ownership | 1.3% |
|---|---|
| Institutional Ownership | 90.9% |
| Short Float | 10.3% |
| % of All Funds Holding | 0.30% |
| Number of Funds Holding | 23 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $2.13 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $3.60 | Medium-term trend |
| Weekly | 80-Week SMA | $2.84 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $4.09 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $3.06 | Near-term monthly trend |
| Monthly | 20-Month SMA | $2.65 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $3.13 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
| Price Level | Type | Volume Ratio | Age |
|---|---|---|---|
| $0.80 | support | 6.04x | 12 months ago |
Next earnings: February 19, 2026
Institutional holder breakdown coming soon.
Total institutional ownership: 90.9%
Total insider ownership: 1.3%
Founder-led management: Arowana (Co-Founder, Executive Chairman & CEO)
Full insider transaction history and smart buy/sell sentiment summary available on Trend Edge.
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for VivoPower PLC (VIVO) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for VIVO on Trend Edge →